Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Plos One|October 27, 2010
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsInes Herrmann, Patrick A Baeuerle, Matthias Friedrich, et al.
Molecular Pharmacology|March 27, 2004
Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory propertiesDietlind Zohlnhöfer, Thomas G Nührenberg, Franz-Josef Neumann, et al.
Cancer Immunology Research|June 6, 2024
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor ActivityNaveen K Mehta, Kavya Rakhra, Kristan A Meetze, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2023
Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptorDerrick McCarthy, Michael Lofgren, Amy Watt, et al.
International Journal of Cancer|July 13, 2002
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatmentStefanie Naundorf, Susanne Preithner, Petra Mayer, et al.
Molecular Immunology|September 27, 2006
A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complexJörg Volkland, John Lumsden, Michael Mølhøj, et al.
Urologia Internationalis|July 8, 2010
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomyNorbert Marschner, Dominik Rüttinger, Gerhard Zugmaier, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 18, 2004
Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplastyThomas G Nührenberg, Rainer Voisard, Felicitas Fahlisch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE classKlaus Brischwein, Larissa Parr, Stefan Pflanz, et al.
Cancer Research|April 19, 2007
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody constructScott A Hammond, Ralf Lutterbuese, Shannon Roff, et al.
Pageof 10